

# Clinical trials of vildagliptin

TrialResults-center [www.trialresultscenter.org](http://www.trialresultscenter.org)

## 1 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
<b>vildagliptin vs</b>			
<a href="#">NCT00101673</a> [NCT00101673] n=NA follow-up:	-	-	
<b>vildagliptin monotherapy vs acarbose</b>			
<a href="#">Pan , 2008</a> [NCT00110240] n=441/220 follow-up: 24 weeks	vildagliptin (100 mg daily, given as 50 mg twice daily versus acarbose (up to 300 mg daily, given as three equally divided doses	drug-naive patients with Type 2 diabetes	double-blind
<b>vildagliptin monotherapy vs gliclazide</b>			
<a href="#">Foley , 2009</a> [NCT00102388] n=NA follow-up: 2 years	monotherapy with vildagliptin 50 mg bid versus gliclazide up to 320 mg/day	drug-naive patients with type 2 diabetes	double-blind
<b>vildagliptin vs gliclazide (add on MET)</b>			
<a href="#">Filozof , 2009</a> [NCT00102466] n=513/494 follow-up: 52 weeks	vildagliptin (50 mg twice daily versus gliclazide (up to 320 mg/day	patients with Type 2 diabetes inadequately controlled with metformin	double-blind
<b>vildagliptin vs glimepiride (add on MET)</b>			
<a href="#">Matthews , 2010</a> n=NA follow-up: 2 years	vildagliptin versus glimepiride	patients with type 2 diabetes mellitus inadequately controlled (HbA1c 6.5-8.5% ) by metformin monotherapy	Parallel groups double-blind
<b>vildagliptin + MET vs MET</b>			
<a href="#">CLAF237A 23104</a> [NCT00396357] n=NA follow-up:	-	-	
<b>vildagliptin vs placebo</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
Mimori , 2006 n=NA follow-up:	vildagliptin 20 mg or 50 mg or 100 mg daily versus placebo	-	
NCT00351832 [NCT00351832] n=NA follow-up: 12 weeks	vildagliptin 50mg qd, 50mg bid or 100mg qd versus placebo	Patients With Type 2 Diabetes	Parallel groups Japan
Rosenstock , 2008 [NCT00237250] n=NA follow-up: 12 weeks	vildagliptin (50 mg q.d.) versus placebo	subjects with impaired glucose tolerance	double-blind
Scherbaum [2] , 2008 [NCT00101712] n=156/150 follow-up: 52 weeks	vildagliptin 50 mg qd versus placebo	drug-naive patients with type 2 diabetes and mild hyperglycaemia	Parallel groups double-blind
<b>vildagliptin monotherapy vs placebo</b>			
Ahren , 2009 [NCT00390520] n=NA follow-up:	vildagliptin (100 mg/d) versus placebo	drug-naive patients with type 2 diabetes	Cross over
Dejager [1] , 2007 [NCT00099905] n=NA follow-up: 24 weeks	vildagliptin 50 mg or 100 mg daily versus placebo	drug-naive patients with type 2 diabetes	double-blind
Foley , 2011 <i>unpublished</i> [NCT00260156] n=29/30 follow-up:	vildagliptin 100 mg versus placebo	drug-naive patients with type 2 diabetes and mild hyperglycaemia	
Kikuchi , 2009 n=NA follow-up:	vildagliptin 50mg bid versus placebo	Japanese patients with type 2 diabetes mellitus	Japan
Pi-Sunyer , 2007 [NCT00120536] n=NA follow-up: 24 weeks	vildagliptin 50 mg or 100 mg daily, imag versus placebo	drug-naive patients with type 2 diabetes	double-blind
Pratley , 2006 n=70/28 follow-up:	vildagliptin 25mg bid versus placebo	-	double-blind

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
Ristic , 2005 n=NA follow-up:	vildagliptin 25mg or 50mg or 100mg daily versus placebo	-	
<b>vildagliptin vs placebo (add on current therapy)</b>			
Lukashevich , 2011 [NA] n=NA follow-up: 24 weeks	vildagliptin (50 mg qd) versus placebo	patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal impairment	
<b>vildagliptin vs placebo (add on glimepiride)</b>			
Kikuchi , 2010 [NCT00325117] n=102/100 follow-up: 12 weeks	vildagliptin 50mg twice-daily versus placebo	Japanese patients with Type 2 diabetes mellitus	double-blind Japan
<b>vildagliptin vs placebo (add on insulin)</b>			
Fonseca , 2007 [NCT00099931] n=144/152 follow-up: 24 weeks	vildagliptin 100 mg daily (add-on to insulin therapy)y) versus placebo (add-on to insulin therapy)y)mag	type 2 diabetes that was inadequately controlled by insulin	double-blind
Fonseca , 2008 n=NA follow-up:	-	-	
<b>vildagliptin vs placebo (add on MET)</b>			
Ahren , 2004 n=56/51 follow-up: 12 weeks	vildagliptin 50 mg daily (add-on to metformin therapy)j versus placebo (add-on to metformin therapy)mag	patients with type 2 diabetes	double-blind
Bosi , 2007 [NCT00099892] n=185/182 follow-up:	vildagliptin (50 or) 100 mg daily (add-on to metformin therapy)m versus placebo (add-on to metformin therapy)mag	patients with type 2 diabetes inadequately controlled with metformin	double-blind
Bosi , 2009 [NCT00382096] n=1179 follow-up: 24 weeks	vildagliptin plus high-dose metformin combination therapy (50 mg + 1000 mg twice daily), versus high-dose metformin monotherapy (1000 mg twice daily).	treatment-naive patients with type 2 diabetes mellitus	

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
Goodman , 2009 n=125/122 follow-up: 24 weeks	ildagliptin 100 mg given in the morning, vildagliptin 100 mg given in the evening versus placebo	patients inadequately controlled with metformin	Parallel groups double-blind
NCT00396071 [NCT00396071] n=NA follow-up:	vildagliptin versus placebo	Patients With Type 2 Diabetes Treated With Metformin	Cross over
NCT00494884 (Wollmer) [NCT00494884] n=NA follow-up:	Vildagliptin 100 mg o.d. versus placebo	Patients With Type 2 Diabetes Inadequately Controlled With Metformin	
NCT00728351 [NCT00728351] n=NA follow-up:	Vildagliptin and Metformin (25/1000 mg Bid) versus Metformin Monotherapy (1000 mg Bid)	Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy	
NCT00822211 [NCT00822211] n=NA follow-up: 24 weeks	Vildagliptin 50 mg Bid or qd versus placebo	Chinese Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy	Parallel groups
<b>vildagliptin vs placebo (add on SU)</b>			
Garber , 2008 [NCT00099944] n=515 follow-up: 24 weeks	vildagliptin (50 mg given once or twice daily) versus placebo	patients with type 2 diabetes inadequately controlled with a sulphonylurea	double-blind
<b>vildagliptin vs placebo (on top pioglitazone)</b>			
Garber , 2007 [NCT00099853] n=463 follow-up:	vildagliptin 50 or 100 mg daily (add-on to pioglitazone therapy) versus placebo (add-on to pioglitazone therapy)	-	
<b>vildagliptin vs Sulphonylurea (add on to MET)</b>			
Ferrannini , 2009 [NCT00106340] n=1396/1393 follow-up: 52 weeks	vildagliptin 50 mg twice daily versus glimepiride titrated up to 6 mg/day	Patients inadequately controlled on metformin monotherapy (HbA(1c) 6.5-8.5% )	Parallel groups double-blind
<b>vildagliptin vs TZD (add on MET)</b>			

continued...

<b>Trial</b>	<b>Treatments</b>	<b>Patients</b>	<b>Trials design and methods</b>
<b>GALIAN (Blonde) , 2009</b> [NCT00396227] n=1653/825 follow-up:	vildagliptin 100 mg versus TZD (agent and dose at the investigators' discretion	patients inadequately controlled [haemoglobin A(1C) (HbA(1c)): 7-10% ] on a stable dose of metformin (>or =1000 mg/day).	
<b>vildagliptin vs voglibose</b>			
<b>Iwamoto , 2010</b> [NA] n=188/192 follow-up: 12 weeks	vildagliptin (50 mg bid, versus voglibose (0.2 mg tid	Japanese patients with T2D who were inadequately controlled with diet and exercise	double-blind Japan
<b>NCT00368134</b> [NCT00368134] n=NA follow-up: 12 weeks	Vildagliptin 50 mg Bid versus Voglibose 0.2 mg Tid	patients with type 2 diabetes	Japan
<b>vildagliptin vs metformin</b>			
<b>Goke , 2008</b> n=NA follow-up:	vildagliptin (100 mg daily) versus metformin (2 000 mg daily).	drug-naive patients with type 2 diabetes	
<b>Schweizer , 2007</b> [NCT00099866] n=526/254 follow-up: 52 weeks	vildagliptin 100mg versus metformin up to 2000 mg daily	drug-naive patients with Type 2 diabetes	
<b>Schweizer , 2009</b> [NCT00246619] n=169/166 follow-up:	vildagliptin (100 mg daily versus metformin (titrated to 1500 mg daily	drug-naive patients with type 2 diabetes aged>or=65 years	
<b>vildagliptin monotherapy vs pioglitazone</b>			
<b>Rosenstock** (vilda vs pio) , 2007</b> [NCT00101803] n=NA follow-up:	vildagliptin 100 mg daily daily versus pioglitazone 30 mg dailyaily	drug-naive patients with type 2 diabetes	double-blind
<b>vildagliptin vs pioglitazone (add on MET)</b>			
<b>Bolli , 2008</b> [NCT00237237] n=295/281 follow-up:	vildagliptin 100 mg daily (add-on to metformin therapy) versus pioglitazone 30 mg daily (add-on to metformin therapy)j	patients with type 2 diabetes inadequately controlled with metformin monotherapy	double-blind
<b>vildagliptin vs placebo (add on TZD)</b>			

continued...

Trial	Treatments	Patients	Trials design and methods
Rosenstock** (vilda + pio vs pio) , 2007 [NCT00101803] n=NA follow-up: 24 weeks	vildagliptin 50 mg or 100 mg daily plus 15 mg or 30 mg pioglitazone daily versus pioglitazone 30 mg daily	drug-naive patients with type 2 diabetes	double-blind
<b>vildagliptin vs rosiglitazone</b>			
Rosenstock , 2009 [NCT00138619] n=396/202 follow-up:	vildagliptin (50 mg b.i.d versus rosiglitazone (8 mg q.d.,	drug-naive type 2 diabetes mellitus patients	double-blind
Rosenstock* (vilda vs rosi) , 2007 [NCT00099918] n=519/267 follow-up: 24 weeks	vildagliptin 100 mg daily daily versus rosiglitazone 8 mg once daily	drug-naive patients with type 2 diabetes	double-blind

More details and results :

- insulin secretagogues for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q409>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on metformin at <http://www.trialresultscenter.org/go-Q509>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on monotherapy at <http://www.trialresultscenter.org/go-Q512>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled with insulin at <http://www.trialresultscenter.org/go-Q513>
- antidiabetic drugs for diabetes type 2 in patients inadequately controlled on TZD at <http://www.trialresultscenter.org/go-Q545>
- insulin secretagogues - DPP-4 inhibitors for diabetes type 2 in all types of patients at <http://www.trialresultscenter.org/go-Q550>

## References

**NCT00101673, :**

Pratley RE, Schweizer A, Rosenstock J, Foley JE, Banerji MA, Pi-Sunyer FX, Mills D, Dejager S Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naive patients: analysis of pooled vildagliptin monotherapy database. Diabetes Obes Metab 2008;10:931-8 [18093207] [10.1111/j.1463-1326.2007.00835.x](https://doi.org/10.1111/j.1463-1326.2007.00835.x)

**Pan, 2008:**

Pan C, Yang W, Barona JP, Wang Y, Niggl M, Mohideen P, Wang Y, Foley JE Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. *Diabet Med* 2008;25:435-41 [18341596] [10.1111/j.1464-5491.2008.02391.x](https://doi.org/10.1111/j.1464-5491.2008.02391.x)

**Foley, 2009:**

Foley JE, Sreenan S Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naive patients with type 2 diabetes. *Horm Metab Res* 2009;41:905-9 [19705345] [10.1055/s-0029-1234042](https://doi.org/10.1055/s-0029-1234042)

**Filozof, 2009:**

Filozof C, Gautier JF A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. *Diabet Med* 2010 Mar;27:318-26 [20536495] [10.1111/j.1464-5491.2010.02938.x](https://doi.org/10.1111/j.1464-5491.2010.02938.x)

**Matthews , 2010:**

Matthews DR, Dejager S, Ahren B, Fonseca V, Ferrannini E, Couturier A, Foley JE, Zinman B Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study. *Diabetes Obes Metab* 2010;12:780-9 [20649630] [10.1111/j.1463-1326.2010.01233.x](https://doi.org/10.1111/j.1463-1326.2010.01233.x)

**CLAF237A 23104, :**

**Mimori, 2006:**

Mimori N, Terao S, Holmes D. *Diabetes* 2006;55(suppl 1):A125

**NCT00351832, :**

**Rosenstock, 2008:**

Rosenstock J, Foley JE, Rendell M, Landin-Olsson M, Holst JJ, Deacon CF, Rochotte E, Baron MA Effects of the dipeptidyl peptidase-IV inhibitor vildagliptin on incretin hormones, islet function, and postprandial glycemia in subjects with impaired glucose tolerance. *Diabetes Care* 2008;31:30-5 [17947341] [10.2337/dc07-1616](https://doi.org/10.2337/dc07-1616)

**Scherbaum [2], 2008:**

Mari A, Scherbaum WA, Nilsson PM, Lalanne G, Schweizer A, Dunning BE, Jauffret S, Foley JE Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia. *J Clin Endocrinol Metab* 2008;93:103-9 [17925336] [10.1210/jc.2007-1639](https://doi.org/10.1210/jc.2007-1639)

Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Jauffret S, Foley JE Efficacy and tolerability of vildagliptin in drug-naive patients with type 2 diabetes and mild hyperglycaemia\*. *Diabetes Obes Metab* 2008 Aug;10:675-82 [18248490] [10.1111/j.1463-1326.2008.00850.x](https://doi.org/10.1111/j.1463-1326.2008.00850.x)

Scherbaum WA, Schweizer A, Mari A, Nilsson PM, Lalanne G, Wang Y, Dunning BE, Foley JE Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. *Diabetes Obes Metab* 2008 Nov;10:1114-24 [18355325] [10.1111/j.1463-1326.2008.00875.x](https://doi.org/10.1111/j.1463-1326.2008.00875.x)

**Ahren, 2009:**

Ahrn B, Schweizer A, Dejager S, Dunning BE, Nilsson PM, Persson M, Foley JE Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. *J Clin Endocrinol Metab* 2009 Apr;94:1236-43 [19174497]

**Dejager [1], 2007:**

Dejager S, Razac S, Foley JE, Schweizer A Vildagliptin in drug-naive patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. *Horm Metab Res* 2007;39:218-23 [17373638] [10.1055/s-2007-970422](https://doi.org/10.1055/s-2007-970422)

**Foley, 2011:**

unpublished

Foley JE, Bunck MC, Miller-Goede DL, Poelma M, Nijpels G, Eekhoff EM, Schweizer A, Heine RJ, Diamant M Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial. *Diabetologia*

2011;54:1985-91 [21547496] [10.1007/s00125-011-2167-8](https://doi.org/10.1007/s00125-011-2167-8)

**Kikuchi, 2009:**

Kikuchi M, Abe N, Kato M, Terao S, Mimori N, Tachibana H Vildagliptin dose-dependently improves glycaemic control in Japanese patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2009;83:233-40 [19118913] [10.1016/j.diabres.2008.10.006](https://doi.org/10.1016/j.diabres.2008.10.006)

**Pi-Sunyer, 2007:**

Pi-Sunyer FX, Schweizer A, Mills D, Dejager S Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. *Diabetes Res Clin Pract* 2007;76:132-8 [17223217] [10.1016/j.diabres.2006.12.009](https://doi.org/10.1016/j.diabres.2006.12.009)

**Pratley, 2006:**

Pratley RE, Jauffret-Kamel S, Galbreath E, Holmes D Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycaemic control in subjects with type 2 diabetes. *Horm Metab Res* 2006;38:423-8 [16823726] [10.1055/s-2006-944546](https://doi.org/10.1055/s-2006-944546)

**Ristic, 2005:**

Ristic S, Byiers S, Foley J, Holmes D Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. *Diabetes Obes Metab* 2005;7:692-8 [16219012] [10.1111/j.1463-1326.2005.00539.x](https://doi.org/10.1111/j.1463-1326.2005.00539.x)

**Lukashevich , 2011:**

Lukashevich V, Schweizer A, Shao Q, Groop PH, Kothny W Safety and efficacy of vildagliptin versus placebo in patients with type 2 diabetes and moderate or severe renal impairment: a prospective 24-week randomized placebo-controlled trial. *Diabetes Obes Metab* 2011;13:947-54 [21733061] [10.1111/j.1463-1326.2011.01467.x](https://doi.org/10.1111/j.1463-1326.2011.01467.x)

**Kikuchi, 2010:**

Kikuchi M, Haneda M, Koya D, Tobe K, Onishi Y, Couturier A, Mimori N, Inaba Y, Goodman M Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus. *Diabetes Res Clin Pract* 2010;89:216-23 [20537746] [10.1016/j.diabres.2010.04.017](https://doi.org/10.1016/j.diabres.2010.04.017)

**Fonseca, 2007:**

Fonseca V, Schweizer A, Albrecht D, Baron MA, Chang I, Dejager S Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. *Diabetologia* 2007;50:1148-55 [17387446] [10.1007/s00125-007-0633-0](https://doi.org/10.1007/s00125-007-0633-0)

**Fonseca , 2008:**

Fonseca V, Baron M, Shao Q, Dejager S Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. *Horm Metab Res* 2008;40:427-30 [18401832] [10.1055/s-2008-1058090](https://doi.org/10.1055/s-2008-1058090)

**Ahren, 2004:**

Ahrn B, Gomis R, Standl E, Mills D, Schweizer A Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. *Diabetes Care* 2004;27:2874-80 [15562200]

**Bosi, 2007:**

Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. *Diabetes Care* 2007;30:890-5 [17277036] [10.2337/dc06-1732](https://doi.org/10.2337/dc06-1732)

**Bosi, 2009:**

Bosi E, Dotta F, Jia Y, Goodman M Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. *Diabetes Obes Metab* 2009;11:506-15 [19320662] [10.1111/j.1463-1326.2009.01040.x](https://doi.org/10.1111/j.1463-1326.2009.01040.x)

**Goodman, 2009:**



Goodman M, Thurston H, Penman J Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. *Horm Metab Res* 2009;41:368-73 [[19221978](#)] [10.1055/s-0028-1104604](#)

**NCT00396071, :**

**NCT00494884 (Wollmer), :**

**NCT00728351, :**

**NCT00822211, :**

**Garber, 2008:**

Garber AJ, Foley JE, Banerji MA, Ebeling P, Gudbjrnsdottir S, Camisasca RP, Couturier A, Baron MA Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. *Diabetes Obes Metab* 2008;10:1047-56 [[18284434](#)] [10.1111/j.1463-1326.2008.00859.x](#)

**Garber, 2007:**

Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. *Diabetes Obes Metab* 2007;9:166-74 [[17300592](#)] [10.1111/j.1463-1326.2006.00684.x](#)

**Ferrannini, 2009:**

Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrn B, Byiers S, Shao Q, Dejager S Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. *Diabetes Obes Metab* 2009;11:157-66 [[19125777](#)] [10.1111/j.1463-1326.2008.00994.x](#)

**GALIAN (Blonde), 2009:**

Blonde L, Dagogo-Jack S, Banerji MA, Pratley RE, Marcellari A, Braceras R, Purkayastha D, Baron M Comparison of vildagliptin and thiazolidinedione as add-on therapy in patients inadequately controlled with metformin: results of the GALIAN trial—a primary care, type 2 diabetes study. *Diabetes Obes Metab* 2009;11:978-86 [[19614942](#)] [10.1111/j.1463-1326.2009.01080.x](#)

**Iwamoto, 2010:**

Iwamoto Y, Kashiwagi A, Yamada N, Terao S, Mimori N, Suzuki M, Tachibana H Efficacy and safety of vildagliptin and voglibose in Japanese patients with type 2 diabetes: a 12-week, randomized, double-blind, active-controlled study. *Diabetes Obes Metab* 2010;12:700-8 [[20590747](#)] [10.1111/j.1463-1326.2010.01222.x](#)

**NCT00368134, :**

**Goke, 2008:**

Gke B, Hershon K, Kerr D, Calle Pascual A, Schweizer A, Foley J, Shao Q, Dejager S Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naive patients with type 2 diabetes: comparison with metformin. *Horm Metab Res* 2008;40:892-5 [[18726829](#)] [10.1055/s-0028-1082334](#)

**Schweizer, 2007:**

Schweizer A, Couturier A, Foley JE, Dejager S Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naive patients with Type 2 diabetes. *Diabet Med* 2007;24:955-61 [[17509069](#)] [10.1111/j.1464-5491.2007.02191.x](#)

Pratley RE, Rosenstock J, Pi-Sunyer FX, Banerji MA, Schweizer A, Couturier A, Dejager S Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy. *Diabetes Care* 2007;30:3017-22 [[17878242](#)] [10.2337/dc07-1188](#)

**Schweizer, 2009:**

Schweizer A, Dejager S, Bosi E Comparison of vildagliptin and metformin monotherapy in elderly patients with type 2 diabetes: a 24-week, double-blind, randomized trial. *Diabetes Obes Metab* 2009;11:804-12 [[19476473](#)] [10.1111/j.1463-1326.2009.01051.x](#)

**Rosenstock\*\* (vilda vs pio), 2007:**

Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. *Diabetes Obes Metab* 2007;9:175-85 [17300593] [10.1111/j.1463-1326.2006.00698.x](https://doi.org/10.1111/j.1463-1326.2006.00698.x)  
**Bolli, 2008:**

Bolli G, Dotta F, Rochotte E, Cohen SE Efficacy and tolerability of vildagliptin vs. pioglitazone when added to metformin: a 24-week, randomized, double-blind study. *Diabetes Obes Metab* 2008;10:82-90 [18034842] [10.1111/j.1463-1326.2007.00820.x](https://doi.org/10.1111/j.1463-1326.2007.00820.x)

Bolli G, Dotta F, Colin L, Minic B, Goodman M Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. *Diabetes Obes Metab* 2009 Jun;11:589-95 [19515179] [10.1111/j.1463-1326.2008.01023.x](https://doi.org/10.1111/j.1463-1326.2008.01023.x)

**Rosenstock\*\* (vilda + pio vs pio), 2007:**

Rosenstock J, Kim SW, Baron MA, Camisasca RP, Cressier F, Couturier A, Dejager S Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. *Diabetes Obes Metab* 2007;9:175-85 [17300593] [10.1111/j.1463-1326.2006.00698.x](https://doi.org/10.1111/j.1463-1326.2006.00698.x)

**Rosenstock, 2009:**

Rosenstock J, Niggli M, Maldonado-Lutomirsky M Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. *Diabetes Obes Metab* 2009 Jun;11:571-8 [19383032]

**Rosenstock\* (vilda vs rosi), 2007:**

Rosenstock J, Baron MA, Dejager S, Mills D, Schweizer A Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. *Diabetes Care* 2007;30:217-23 [17259484] [10.2337/dc06-1815](https://doi.org/10.2337/dc06-1815)

Rosenstock J, Niggli M, Maldonado-Lutomirsky M Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naive patients with type 2 diabetes mellitus. *Diabetes Obes Metab* 2009 Jun;11:571-8 [19383032] [10.1111/j.1463-1326.2008.01021.x](https://doi.org/10.1111/j.1463-1326.2008.01021.x)

Entry terms: vildagliptin, (2S)-(((3-hydroxyadamantan-1-yl)amino)acetyl)pyrrolidine-2-carbonitrile, NVP-LAF237, Galvus,